GlassScriptPhysician profile
Daniel R Doman
NPI 1194712471
$4,768.62
in general payments reported to CMS, 2019-2025
38 companies · $90.51 in 2025
The $90.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $972 · 2022: $183 · 2023: $737 · 2024: $1,166 · 2025: $90.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $718.82 | 2019-2025 | |
| Novo Nordisk INC | $672.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $512.96 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $335.98 | 2019-2024 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $241.70 | 2019-2020 | |
| Lilly USA, LLC | $213.01 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $211.78 | 2019-2020 | |
| Abbvie INC. | $205.77 | 2022-2024 | Viberzi, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $188.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $138.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $124.83 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $111.14 | 2019-2020 | |
| Corium, LLC | $95.56 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $90.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.10 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Doman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.